2020
ESMO Virtual Congress, September 19-21, 2020.
- Final Results from ILLUMINATE-204, a Phase 1/2 Trial of Intratumoral Tilsotolimod in Combination with Ipilimumab in PD-1 Inhibitor Refractory Advanced Melanoma
- Phase 1b Trial of ABBV-368 + Tilsotolimod in Combination With Nab-Paclitaxel and/or Budigalimab (ABBV-181) in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AACR Annual Meeting, Virtual Meeting I, April 27 – 28, 2020
2019
European Society for Medical Oncology 2019 Congress, Barcelona, Spain, September 27 – October 1, 2019
AACR 2019 Annual Meeting, Atlanta, GA, March 29 – April 3, 2019
2018
European Society for Medical Oncology 2018 Congress, Munich, Germany, October 19 – 23, 2018
- The Safety and Efficacy of Intratumoral Injection of the TLR9 Agonist Tilsotolimod (IMO-2125) in Combination with Ipilimumab in Patients with PD-1 inhibitor Refractory Metastatic Melanoma: An Analysis of Efficacy in Injected and Uninjected Lesions.
- A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma.
International Journal of Oncology, September 2018
2018 ASCO Annual Meeting, Chicago, IL, June 1 – 5, 2018
AACR 2018 Annual Meeting, Chicago, IL, April 14 – 18, 2018
2017
SITC 2017 Annual Meeting, National Harbor, MD, November 8 – 12, 2017
- TLR9 Agonist Harnesses Innate Immunity Poster Presentation
- IMO-2125 SITC Oral Presentation
ESMO 2017 Congress, Madrid, Spain, September 8 – 12, 2017
Third Annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz, Germany, September 6 – 9, 2017
AACR 2017 Annual Meeting, Washington, DC, April 1 – 5, 2017
- Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase 1/2 study in patients with anti-PD-1 refractory metastatic melanoma
- Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer
OPT Boston 2017, Cambridge, MA, March 27 – 29, 2017
2017 ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, February 23 – 25, 2017
2016
SITC 2016 Annual Meeting, National Harbor, MD, November 9 – 13, 2016
- IMO-2125 – An Investigational Intratumoral Toll-Like Receptor 9 Agonist Modulates the Tumor Microenvironment
- Reactivating the Anti-Tumor Response By Targeting Innate and Adaptive Immunity in a Trial of Intratumoral IMO-2125-oral presentation
- Reactivating the Anti-Tumor Response by Targeting Innate and Adaptive Immunity in a Trial of Intratumoral IMO-2125-poster
AACR 2016 Annual Meeting, New Orleans, LA, April 16 – 20, 2016
2015
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5 – 9, 2015
CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference, New York, NY, September 16 – 19, 2015
- Intratumoral Administration of IMO-2125, a Novel TLR9 Agonist, Modulates the Tumor Microenvironment and Exerts Systemic Antitumor Activity Alone and in Combination with an Anti-CTLA-4 mAb
- Modulation of Checkpoint Expression in Tumor Microenvironment by Intratumoral Administration of a Novel TLR9 Agonist: Rationale for Combination Therapy